The goal of this clinical trial is to learn if drugs (fludarabine and melphalan) combinated with a targeted irradiation (in bone marrow and in lymphoid tissue) works to treat blood cancers (high risk myelodysplastic syndrome or acute myeloid leukemia) in adults. It will also learn about the safety of this combination of drugs and irradiation. The main questions it aims to answer are:
* Does this combined therapy result in an improved survival and decreased relapse/progression rate after a bone marrow transplant? * What toxicities or complications do participants have when taking this combined therapy?
Researchers will use this combined therapy to see if it works to treat high risk myelodysplastic syndrome or acute myeloid leukemia through the evaluation of the length of time (during the treatment and 2 years after the treatment) that a patient lives with the disease but it does not get worse (progression-free survival).
Participants will:
* Receive the combined therapy (study treatment) one week before the bone marrow transplant. * Receive too post-transplant medication as per usual clinical practice.
Patients will have to attend medical visits (checkups and tests) for 2 years.
The participant has the ability and willingness to sign the informed consent document. (For adults, only participants with mild cognitive abilities may use a legally authorized representative).
Documented (signed) informed consent. The patient, family member, and doctor of the transplant staff (doctor, nurse, and social worker) meet at least once before the transplant procedure begins. During this meeting, all relevant information regarding the risks and benefits to the donor and recipient will be presented. Alternative treatment modalities will be discussed. The risks are explained in detail in the attached consent forms.
Age: ≥ 50 years or Haematopoietic Cell Transplantation-Comorbidity Index pre-transplant score ≥ 3 or any other condition that precludes the use of a fully myeloablative conditioning regimen.
Karnofsky's performance status ≥ 70%.
Patients who have received a previous autologous (within the last year) or allogeneic transplant (at any time) are excluded.
Previous radiation therapy which would preclude the use of TMLI.
Plans during the trial to receive any other investigational (non-trial-related) agents.
Uncontrolled disease, including ongoing or active infection.
Sequential
TMLI/Flu/Mel
Combination productTargeted total bone marrow and lymphoid irradiation (TMLI) conformal therapy administered in combination with a reduced-intensity regimen based on Fludarabine and Melphalan.
Progression-free survival
Time from the start of treatment to the date of death, disease relapse/progression, or date of last follow-up.
Overall survival
Quantification of time of patients who are still alive.
Cumulative incidence of recurrence/progression
The event is relapse/progression either extramedullary or at bone marrow
Complete remission date
The event is whether or not the patient has a documented complete remission.
Non-relapse mortality
Number of deaths from causes other than relapse or progression.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
